Abstract: A bracket (14) has a first surface (18) and a second surface (19). The first surface (18) is attached to a panel (2) made of metal, the panel (2) constituting at least a portion of an accommodation chamber (3) in which a vibration source (4) is accommodated. The second surface (19) is positioned on a side opposite the first surface (18), and in order to guard the panel (2) from contact with a wire harness (8), which is routed inside the accommodation chamber, when the wire harness (8) receives vibration from the vibration source (4), the second surface (19) contacts the wire harness (8).

Abstract: As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.

Abstract: Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.

Abstract: Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.

Abstract: An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on a serotonin 5-HT5A receptor modulating action. It was confirmed that acylguanidine derivatives, which has the characteristic structure in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent 5-HT5A receptor modulating action and excellent pharmacological action based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

Abstract: An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia, and the like, based on the serotonin 5-HT5A receptor modulating action. It was confirmed that a bicyclic acylguanidine derivative which has a characteristic structure that guanidine is bonded to one ring of a bicyclic structure such as chromene and dihydronaphthalene through a carbonyl group and a cyclic group is bonded on the other ring, has a potent 5-HT5A receptor modulating action and an excellent pharmacological action based on this mechanism. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder.

Abstract: [Problem] To provide a compound which is useful as a GK activator. [Means for Resolution] As a result of an extensive study on thiazole derivatives, the present inventors have found that a compound having an oxamoyl group, a glycol group or the like on a thiazole ring and a compound having an acetamide group substituted by a bicyclic heteroaryl group such as a quinolyl have a good GK activation effect, and thereby have accomplished the present invention. Since the compounds of the present invention have a good GK activation effect, these are useful as therapeutic agents for diabetes, particularly type II diabetes.

Abstract: A charging area display apparatus for vehicle comprises a storage device that stores in memory roadmap data and charging area data, a current position detection device that detects a current position of a vehicle, a display device that displays a roadmap, an approach judging device that judges whether or not the vehicle is approaching a charging area based upon the current vehicle position and the charging area data and a scaling factor change device that changes the scaling factor of the roadmap displayed on the display device so as to contain both the current vehicle position and the entirety of the charging area which the vehicle is approaching within the display screen when the vehicle is judged to be approaching the charging area. In this vehicle charging area display apparatus, the display device displays the current vehicle position and the charging area which the vehicle is approaching on the roadmap, the scaling factor of which has been changed as the vehicle approaches the charging area.

Abstract: A method and apparatus for performing data communication between an on-board short-range communication apparatus 1, which is able to comply with a plurality of applications, and an on-road device 2 located in the vicinity of a road on which a vehicle travels, is disclosed. A data analyzing and controlling unit 3 is operative to permit an information providing unit 10 to provide information of entire one of or a portion of the applications installed in the on-board short-range communication apparatus in response to turning-on of an electric power supply 5 of the apparatus and to provide information of entire one of or a portion of the applications prepared in an IC card 12 responsive to insertion of the IC card to an IC card read out unit 6.

Abstract: A charging area display apparatus for vehicle comprises a storage device that stores in memory roadmap data and charging area data, a current position detection device that detects a current position of a vehicle, a display device that displays a roadmap, an approach judging device that judges whether or not the vehicle is approaching a charging area based upon the current vehicle position and the charging area data and a scaling factor change device that changes the scaling factor of the roadmap displayed on the display device so as to contain both the current vehicle position and the entirety of the charging area which the vehicle is approaching within the display screen when the vehicle is judged to be approaching the charging area. In this vehicle charging area display apparatus, the display device displays the current vehicle position and the charging area which the vehicle is approaching on the roadmap, the scaling factor of which has been changed as the vehicle approaches the charging area.